Pathkey.AI Reports $3.65 Million FY26 Loss with $36.7 Million Chipforge Acquisition
Pathkey.AI Ltd (ASX:PKY) reported a $3.65 million loss for FY26 while marking key milestones in its AI-driven semiconductor design and clinical trial forecasting platforms. The company completed its acquisition of Chipforge Pte Ltd, expanding its AI capabilities and preparing for commercialisation in FY27.
- FY26 net loss of $3.65 million, revenue of $47,632
- Completed $36.7 million asset acquisition of Chipforge Pte Ltd
- Chipforge produced FPGA-capable designs, targeting FY27 commercial rollout
- TrialKey platform development and marketing advanced for broader adoption
- Raised $4.66 million during FY26 plus $2.8 million post-year-end placement
Chipforge Acquisition Boosts AI Semiconductor Ambitions
Pathkey.AI Ltd (ASX:PKY) took a significant leap this financial year by completing the acquisition of Singapore-based Chipforge Pte Ltd, an AI-driven semiconductor design company. The deal, valued at over $36.7 million in intellectual property plus cash and transaction costs, was accounted for as an asset acquisition. This strategic move broadens Pathkey’s AI platform reach beyond clinical trial forecasting into the semiconductor industry, targeting a market traditionally constrained by high costs and scarce engineering expertise.
Chipforge’s AI-native platform translates high-level design intent expressed in natural language into verified hardware code that can be implemented on FPGAs (field-programmable gate arrays). FY26 saw the platform achieve a critical milestone by producing working FPGA-capable designs, paving the way for commercial deployment planned in FY27. The company aims to offer flexible deployment options, including public cloud, private cloud, and air-gapped environments, catering to customers with stringent security requirements.
TrialKey Advances Clinical Trial AI with Commercial Focus
Alongside Chipforge, Pathkey’s TrialKey platform continued to develop as a forecasting and simulation tool for clinical trials. TrialKey leverages decades of curated trial data and large language models to predict trial success probabilities and optimise trial designs. The company expanded its business development efforts, including appointing a dedicated manager and participating in major industry conferences.
FY27 plans include automating trial protocol document creation and enhancing AI capabilities to anticipate operational issues before trials commence. These improvements aim to reduce manual effort and improve trial success rates, potentially unlocking significant cost savings for sponsors in an industry where most costs are committed upfront.
Financial Performance and Capital Raising
Pathkey reported a net loss after tax of $3.65 million for FY26, more than doubling the prior year’s $1.45 million loss, with revenue modest at $47,632. The company raised $4.66 million during the year through a mix of placements, rights issues, and option exercises, supplemented by a $2.8 million strategic placement post year-end. These funds underpin ongoing development, commercialisation efforts, and expansion of engineering teams across Australia, Singapore, and India.
Issued capital swelled to over 1.2 billion shares by June 2026, reflecting the capital raises and the Chipforge acquisition consideration. The company has no dividends planned, focusing resources on growth and technology commercialisation.
Governance, Risks, and Leadership Changes
Board and management changes included the appointment of Shannon Robinson as Non-Executive Chair in late 2025 and Andrew Farnsworth as CEO in May 2026, bringing defence and AI expertise to accelerate commercialisation. The company also appointed Sam Weiss as a strategic advisor post-year-end, linked to the $2.8 million placement.
Key risks flagged include retention of specialised personnel, competition from larger incumbents, data security threats, export controls related to semiconductor technology, and integration challenges following the Chipforge acquisition. The company is actively managing these risks while building its sales pipeline and secure infrastructure capabilities.
Looking Ahead to FY27
Pathkey’s immediate priorities focus on converting Chipforge platform demonstrations into paid customer engagements and expanding engineering capacity. For TrialKey, the emphasis is on enhancing platform automation and scaling marketing efforts to drive revenue growth. The company’s dual-platform approach targets two large, high-value markets with long-established workflows and significant inefficiencies ripe for AI disruption.
The successful integration and commercialisation of Chipforge alongside TrialKey will be critical to Pathkey’s ability to move from development to revenue generation. With a strengthened leadership team and fresh capital, the company faces a pivotal year as it seeks to translate its AI innovations into tangible market traction.
Bottom Line?
Pathkey’s FY26 investments in AI chip design and clinical trial platforms set the stage for commercialisation, but execution risks and financial losses highlight the challenge ahead.
Questions in the middle?
- How quickly can Chipforge convert its FPGA design milestone into paying customers?
- Will TrialKey’s planned automation and marketing efforts translate into meaningful revenue growth in FY27?
- How will Pathkey manage integration and regulatory risks tied to its semiconductor technology expansion?
